Literature DB >> 2657953

Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice.

J Gade1, P Thorn.   

Abstract

A comparison of Paraghurt tablets (freeze-dried culture of Streptococcus faecium) and placebo was carried out in patients with irritable bowel syndrome in a double-blind trial in Danish general practices. Fifty-four patients (42 females and 12 males) with an average duration of the disease of seven years were treated for four weeks. The clinical symptoms were registered prior to the treatment and after two and four weeks. The clinical effect was assessed according to changes in number of abdominal symptoms, the patients' registrations on rating scales, and the physicians' overall estimations. According to all three parameters a markedly better effect of Paraghurt was seen. Thus, after four weeks 81% of the Paraghurt- and 41% of the placebo-treated patients had improved according to the physicians' overall assessment (p = 0.002). The result of the trial suggests that Paraghurt is a valuable alternative in the treatment of irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657953     DOI: 10.3109/02813438909103666

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  17 in total

1.  Do probiotics improve symptoms in patients with irritable bowel syndrome?

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 3.  Treatment of irritable bowel syndrome: a review of randomised controlled trials.

Authors:  R Akehurst; E Kaltenthaler
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 4.  Actual concept of "probiotics": is it more functional to science or business?

Authors:  Michele Caselli; Francesca Cassol; Girolamo Calò; John Holton; Giovanni Zuliani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

Review 5.  Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  William E Bennett
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

Review 6.  New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics.

Authors:  Rachna Patel; Herbert L DuPont
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 7.  Meta-analysis of probiotics for the treatment of irritable bowel syndrome.

Authors:  Lynne V McFarland; Sascha Dublin
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

8.  Intestinal microbiota in functional bowel disorders: a Rome foundation report.

Authors:  Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal
Journal:  Gut       Date:  2012-06-22       Impact factor: 23.059

9.  A meta-analysis of probiotic efficacy for gastrointestinal diseases.

Authors:  Marina L Ritchie; Tamara N Romanuk
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

Review 10.  A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.

Authors:  Nourieh Hoveyda; Carl Heneghan; Kamal R Mahtani; Rafael Perera; Nia Roberts; Paul Glasziou
Journal:  BMC Gastroenterol       Date:  2009-02-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.